Title

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle.
  • Phase

    N/A
  • Study Type

    Interventional
  • Intervention/Treatment

    celecoxib ...
  • Study Participants

    11
The investigators propose to test the hypothesis that the use of a prostaglandin inhibitor will result in premature luteolysis (ovulation failure) in women.
Currently available methods of emergency contraception (EC) only work during a very narrow time period prior to the hormonal trigger for ovulation or the release of an egg. Women having unprotected sex outside this window receive no benefits from this emergency therapy. Prostaglandins are critical before, during, and after ovulation, thus their inhibition may cause an EC effect that works over a longer time period. We wanted to determine if celecoxib might work as an EC with a wider window of action.
Study Started
Jan 31
2008
Primary Completion
Aug 31
2008
Study Completion
Aug 31
2008
Results Posted
Jul 04
2012
Estimate
Last Update
Dec 13
2012
Estimate

Drug Celebrex

One 400mg tablet daily.

Drug Placebo

One tablet daily.

1 Experimental

2 Placebo Comparator

Criteria

Inclusion Criteria:

Age 18-35
Normal menstrual periods (24-35 days)
Good general health
Willing to use a non-hormonal form of contraception for the entire study (Acceptable forms of contraception include condoms, spermicide, sexual contact with a sterilized partner, subject is surgically sterile, same-sex partner, Copper IUD and abstinence)
Willing and able to return to clinic for bi-weekly blood tests

Exclusion Criteria:

Pregnant or breast feeding
Polycystic ovarian disease
Gastrointestinal conditions (i.e.gastric ulcer)
Currently using birth control
Known allergy to aspirin, non-steroidal anti-inflammatory drugs (NSAIDS) or Sulfa-drugs
Diabetes
Cardiac disease or hypertension
Moderate to severe heartburn (GERD)
Obesity (BMI greater than 30)

Summary

Active Drug Cycle

Placebo

All Events

Event Type Organ System Event Term

Menstrual Cycle Length

Menstrual cycle length was measured by the number of days subjects noted menstruating in their diary entry.

Active Drug

28.5
Days (Mean)
Standard Deviation: 2.5

Placebo

27.2
Days (Mean)
Standard Deviation: 2.4

Total

11
Participants

Age Continuous

27.85
years (Mean)
Standard Deviation: 0.0

Region of Enrollment

Sex: Female, Male

Overall Study

Active Drug Cycle

Placebo